Parallel Advisors
CMPX icon

Parallel Advisors’s Compass Therapeutics CMPX Stock Holding History

Parallel Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$357 Buy
+343
New +$707 ﹤0.01% 3932
2026
Q2 		– Sell
-5,250
Closed -$27.8K – 3950
2026
Q1 		$27.8K Buy
+5,250
New +$30.3K ﹤0.01% 2319

Other funds holding CMPX

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Caitong International Asset Management
Caitong International Asset Management Hong Kong $1.04B AUM 150.25% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Profund Advisors
Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Simplicity Wealth
Simplicity Wealth Summit, New Jersey $3.43B AUM 16.22% 1-Year Est. Return
Independent Financial Group
Independent Financial Group San Diego, California $5.51B AUM 33.51% 1-Year Est. Return

Parallel Advisors's CMPX Position: Q3 2026 in Review

Parallel Advisors opened a new position in Compass Therapeutics (CMPX) in Q3 2026: 343 shares worth $357. The stake represents ﹤0.01% of the portfolio and ranks #3932 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in CMPX as recently as Q1 2026.

Parallel Advisors first reported a position in CMPX in Q1 2026 and has held it in 2 quarters since. The position peaked at $27.8K in Q1 2026. 33 funds tracked by Wall St. Rank hold CMPX as of Q3 2026.

  • Parallel Advisors held 343 shares of Compass Therapeutics worth $357 as of Q3 2026.
  • Compass Therapeutics was a new Parallel Advisors position in Q3 2026.
  • Compass Therapeutics made up ﹤0.01% of Parallel Advisors's portfolio in Q3 2026, its #3932 holding.
  • Parallel Advisors first reported a position in Compass Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Parallel Advisors's Compass Therapeutics position peaked at $27.8K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Compass Therapeutics as of Q3 2026.

Based on Parallel Advisors's 13F filing for Q3 2026, filed 3 Nov 2026.